BRPI0610322B8 - inibidores de sinalização de receptor de vegf e de receptor de hgf e composição farmacêutica - Google Patents

inibidores de sinalização de receptor de vegf e de receptor de hgf e composição farmacêutica

Info

Publication number
BRPI0610322B8
BRPI0610322B8 BRPI0610322A BRPI0610322A BRPI0610322B8 BR PI0610322 B8 BRPI0610322 B8 BR PI0610322B8 BR PI0610322 A BRPI0610322 A BR PI0610322A BR PI0610322 A BRPI0610322 A BR PI0610322A BR PI0610322 B8 BRPI0610322 B8 BR PI0610322B8
Authority
BR
Brazil
Prior art keywords
receptor signaling
hgf
pharmaceutical composition
receptor
signaling inhibitors
Prior art date
Application number
BRPI0610322A
Other languages
English (en)
Inventor
Wahhab Amal
Vaisburg Arkadii
Raeppel Franck
Gaudette Frederic
Zhan Lijie
Isakovic Ljubomir
Granger Marie-Claude
Mannion Michael
Zhou Nancy
Bernstein Naomy
Mario Saavedra Oscar
Deziel Robert
Raeppel Stephane
William Claridge Stephen
Original Assignee
Methylgene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Methylgene Inc filed Critical Methylgene Inc
Publication of BRPI0610322A2 publication Critical patent/BRPI0610322A2/pt
Publication of BRPI0610322B1 publication Critical patent/BRPI0610322B1/pt
Publication of BRPI0610322B8 publication Critical patent/BRPI0610322B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

inibidores de sinalização de receptor de vegf e receptor de hgf. a presente invenção refere-se à inibição de sinalização de receptor de vegf e sinalização de receptor de hgf. a invenção fornece compostos e métodos para inibição da sinalização de receptor de vegf e sinalização de receptor de hgf. a invenção também fornece composições e métodos para tratar doenças e condições proliferativas celulares.
BRPI0610322A 2005-05-20 2006-05-19 inibidores de sinalização de receptor de vegf e de receptor de hgf e composição farmacêutica BRPI0610322B8 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US68303605P 2005-05-20 2005-05-20
US60/683,036 2005-05-20
US75490205P 2005-12-29 2005-12-29
US60/754,902 2005-12-29
US78505406P 2006-03-22 2006-03-22
US60/785,054 2006-03-22
PCT/IB2006/004306 WO2008041053A2 (en) 2005-05-20 2006-05-19 Inhibitors of vegf receptor and hgf receptor signaling

Publications (3)

Publication Number Publication Date
BRPI0610322A2 BRPI0610322A2 (pt) 2010-06-15
BRPI0610322B1 BRPI0610322B1 (pt) 2020-12-01
BRPI0610322B8 true BRPI0610322B8 (pt) 2021-05-25

Family

ID=39190471

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0610322A BRPI0610322B8 (pt) 2005-05-20 2006-05-19 inibidores de sinalização de receptor de vegf e de receptor de hgf e composição farmacêutica

Country Status (13)

Country Link
US (2) US8093264B2 (pt)
EP (1) EP1957498B1 (pt)
JP (1) JP5148499B2 (pt)
KR (1) KR101378716B1 (pt)
CN (1) CN101796055B (pt)
AU (1) AU2006343808B2 (pt)
BR (1) BRPI0610322B8 (pt)
CA (1) CA2611370C (pt)
ES (1) ES2623221T3 (pt)
IL (1) IL187484A (pt)
MX (1) MX2007014616A (pt)
NZ (1) NZ564283A (pt)
WO (1) WO2008041053A2 (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7276519B2 (en) * 2002-11-25 2007-10-02 Wyeth Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
CA2573538C (en) * 2004-07-30 2014-11-25 Methylgene Inc. Inhibitors of vegf receptor and hgf receptor signaling
ES2473341T3 (es) 2005-05-20 2014-07-04 Methylgene Inc Inhibidores de la se�alizaci�n del receptor del VEGF y del receptor del HGF
AR056200A1 (es) * 2005-09-27 2007-09-26 Wyeth Corp Tieno [2,3-b]piridin-5-carbonitrilos como inhibidores de proteina quinasa
AR059246A1 (es) * 2006-01-30 2008-03-19 Array Biopharma Inc Compuestos heterobiciclicos de tiofeno y metodos de uso
MX2008011220A (es) * 2006-03-07 2008-09-11 Array Biopharma Inc Compuestos de pirazol heterobiciclicos y metodos de uso.
WO2007107005A1 (en) * 2006-03-22 2007-09-27 Methylgene, Inc. Inhibitors of protein tyrosine kinase activity
JP5302883B2 (ja) 2006-04-07 2013-10-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 医薬組成物用のｍｎｋ１／ｍｎｋ２阻害活性を有するチエノピリミジン
US20110053931A1 (en) * 2006-06-08 2011-03-03 John Gaudino Quinoline compounds and methods of use
EP1889847A1 (en) 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidines for pharmaceutical compositions
EP2183254B1 (en) * 2007-08-29 2017-06-21 MethylGene Inc. Inhibitors of protein tyrosine kinase activity
WO2009026720A1 (en) * 2007-08-29 2009-03-05 Methylgene Inc. Processes and intermediates for preparing fused heterocyclic kinase inhibitors
WO2009026701A1 (en) * 2007-08-29 2009-03-05 Methylgene Inc. Sirtuin inhibitors
US8906647B2 (en) 2008-02-21 2014-12-09 Sequoia Pharmaceuticals, Inc. Diamide inhibitors of cytochrome P450
WO2009109035A1 (en) * 2008-03-05 2009-09-11 Methylgene Inc. Inhibitors of protein tyrosine kinase activity
KR20110045019A (ko) 2008-08-26 2011-05-03 베링거 인겔하임 인터내셔날 게엠베하 약제학적 조성물을 위한 티에노피리미딘
CA2740746A1 (en) * 2008-10-14 2010-04-22 Ning Xi Compounds comprising a spiro-ring and and methods of use
CN102256493A (zh) * 2008-10-29 2011-11-23 迪赛孚尔制药有限公司 表现出抗癌活性和抗增殖活性的环丙烷酰胺及其类似物
EP2408300B1 (en) * 2009-03-21 2016-05-11 Sunshine Lake Pharma Co., Ltd. Amino ester derivatives, salts thereof and methods of use
AU2010339444A1 (en) 2009-12-30 2012-07-19 Arqule, Inc. Substituted pyrrolo-aminopyrimidine compounds
UY33241A (es) 2010-02-26 2011-09-30 Boehringer Ingelheim Int ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
EA201201191A1 (ru) 2010-02-26 2013-04-30 Бёрингер Ингельхайм Интернациональ Гмбх 4-[циклоалкилокси(гетеро)ариламино]тиено[2,3-d]пиримидины, обладающие ингибирующей активностью по отношению к mnkl/mnk2, предназначенные для фармацевтических композиций
AR080328A1 (es) 2010-02-26 2012-03-28 Boehringer Ingelheim Int Tienopirimidinas que contienen un grupo alquilo sustituido inhibidoras de quinasas mnk1 y/o mnk2, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento de trastornos metabolicos tales como diabetes y obesidad, y trastornos hiperproliferativos, entre otros
CN101863911A (zh) * 2010-04-13 2010-10-20 艾琪康医药科技（上海）有限公司 一种1-r1-3,4-脱氢-3或4-r6-哌啶的制备方法
PH12012502073A1 (en) * 2010-04-16 2013-02-11 Methylgene Inc Inhibitors of protein tyrosine kinase activity
US20130225581A1 (en) 2010-07-16 2013-08-29 Kyowa Hakko Kirin Co., Ltd Nitrogen-containing aromatic heterocyclic derivative
US8664244B2 (en) 2010-09-12 2014-03-04 Advenchen Pharmaceuticals, LLC Compounds as c-Met kinase inhibitors
RU2568258C2 (ru) 2011-02-28 2015-11-20 Саншайн Лейк Фарма Ко., Лтд Замещенные соединения хинолина и способы их использования
WO2014079545A1 (en) 2012-11-20 2014-05-30 Ktb Tumorforschungsgesellschaft Mbh Thioether derivatives as protein kinase inhibitors
WO2015162515A1 (en) 2014-04-25 2015-10-29 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
CN105348213A (zh) * 2015-09-22 2016-02-24 武汉理工大学 β-氟烷基-β-氨基酸类化合物的制备方法
FR3041640B1 (fr) 2015-09-30 2019-05-17 Les Laboratoires Servier NOUVEAUX DERIVES DE PYRROLO[2,3-d]PYRIMIDINE, LEUR PROCEDE DE PREPRATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
SG11201901197PA (en) 2016-08-24 2019-03-28 Arqule Inc Amino-pyrrolopyrimidinone compounds and methods of use thereof
CN108530464B (zh) * 2017-03-02 2020-10-27 深圳海王医药科技研究院有限公司 一种多靶点激酶抑制剂
ES2974634T3 (es) 2018-12-21 2024-06-28 Celgene Corp Inhibidores de tienopiridinas de RIPK2
CN110423218A (zh) * 2019-08-09 2019-11-08 新乡双鹭药业有限公司 一种苹果酸卡博替尼合成中杂质的制备方法
CN113336768B (zh) * 2020-02-18 2022-08-19 深圳海王医药科技研究院有限公司 一种多靶点酪氨酸激酶抑制剂
CN114957136A (zh) * 2021-02-24 2022-08-30 南京科默生物医药有限公司 一种用作vegfr抑制剂的抗肿瘤化合物及其用途
CN115215803B (zh) * 2022-09-19 2022-12-30 苏州美诺医药科技有限公司 一种4-卤代-1-(二氟甲基)-1h-咪唑的制备方法
CN117902987A (zh) * 2024-01-22 2024-04-19 安庆双启医药科技有限公司 一种3-氟-5-碘苯胺的制备方法
WO2025239980A1 (en) * 2024-05-13 2025-11-20 University Of Virginia Patent Foundation Compounds for the inhibition of kifc3, methods of making the same, and pharmaceutical compositions comprising the same
WO2026086911A1 (en) * 2024-10-24 2026-04-30 Fujian Haixi Pharmaceuticals Co., Ltd. Tyrosine kinase inhibitors and uses thereof

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0889122A3 (en) 1993-11-30 1999-03-03 McGILL UNIVERSITY Inhibition of DNA Methyltransferase
US5578716A (en) 1993-12-01 1996-11-26 Mcgill University DNA methyltransferase antisense oligonucleotides
US6107300A (en) 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
US6268137B1 (en) 1996-05-22 2001-07-31 Methylgene, Inc. Specific inhibitors of DNA methyl transferase
US6020318A (en) 1997-05-30 2000-02-01 Methylgene, Inc. DNA methyltransferase genomic sequences and antisense oligonucleotides
AU8125098A (en) 1997-05-30 1998-12-30 Mcgill University Dna methyltransferase genomic sequences and antisense oligonucleotides
WO1999024440A1 (en) * 1997-11-11 1999-05-20 Pfizer Products Inc. Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
US6066625A (en) 1998-02-03 2000-05-23 Methylgene, Inc. Optimized antisense oligonucleotides complementary to DNA methyltransferase sequences
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
KR20010052570A (ko) 1998-06-04 2001-06-25 스티븐 에프. 웨인스톡 세포 유착을 억제하는 소염성 화합물
US6953783B1 (en) 1998-10-19 2005-10-11 Methylgene, Inc. Modulation of gene expression by combination therapy
GB9906566D0 (en) 1999-03-23 1999-05-19 Zeneca Ltd Chemical compounds
WO2000071703A2 (en) 1999-05-03 2000-11-30 Methylgene Inc. Inhibition of histone deacetylase
HK1045306A1 (zh) 1999-06-03 2002-11-22 Abbott Laboratories 抑制细胞黏附的抗炎化合物
CA2391952C (en) 1999-11-23 2012-01-31 Methylgene Inc. Inhibitors of histone deacetylase
EP1438404A2 (en) 2000-03-24 2004-07-21 Methylgene, Inc. Inhibition of specific histone deacetylase isoforms
AU2001248701A1 (en) 2000-03-24 2001-10-03 Methylgene, Inc. Inhibitors of histone deacetylase
AU2001252463A1 (en) 2000-06-06 2001-12-17 Pfizer Products Inc. Thiophene derivatives useful as anticancer agents
US20020004511A1 (en) 2000-06-28 2002-01-10 Luzzio Michael Joseph Thiophene derivatives useful as anticancer agents
EP1415987B1 (en) * 2000-10-20 2007-02-28 Eisai R&D Management Co., Ltd. Nitrogenous aromatic ring compounds as anti cancer agents
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
WO2003000194A2 (en) 2001-06-21 2003-01-03 Pfizer Inc. Thienopyridine and thienopyrimidine anticancer agents
CA2454538A1 (en) * 2001-06-22 2003-01-03 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives capable of inhibiting autophosphorylation of hepatocyte growth factor receptors, and pharmaceutical composition comprising the same
WO2003024448A2 (en) 2001-09-14 2003-03-27 Methylgene, Inc. Inhibitors of histone deacetylase
US6897220B2 (en) 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
US7868204B2 (en) 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
JP2005527511A (ja) 2002-03-01 2005-09-15 ファイザー インコーポレイテッド 抗血管形成剤として有用なチエノピリジンのインドリル−尿素誘導体およびその使用法
EP1551795A1 (en) 2002-10-17 2005-07-13 Methylgene, Inc. Inhibitors of histone deacetylase
CL2003002287A1 (es) 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
CA2536321A1 (en) * 2003-08-29 2005-03-10 Pfizer Inc. Thienopyridine-phenylacet amides and their derivatives useful as new anti-angiogenic agents
CA2539117A1 (en) 2003-09-24 2005-04-07 Methylgene Inc. Inhibitors of histone deacetylase
CA2744997A1 (en) * 2003-09-26 2005-04-07 Exelixis, Inc. C-met modulators and method of use
WO2005052872A1 (en) 2003-11-21 2005-06-09 Facil, Llc Financial transaction system and method
CA2553433A1 (en) 2004-01-23 2005-08-11 Amgen Inc. Quinoline quinazoline pyridine and pyrimidine compounds and their use in the treatment of inflammation angiogenesis and cancer
EP1735319B1 (en) 2004-03-26 2017-05-03 MethylGene Inc. Inhibitors of histone deacetylase
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
WO2005121125A1 (en) * 2004-06-09 2005-12-22 Pfizer Inc. Ether-linked heteroaryl compounds
US7439246B2 (en) 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
US20050288290A1 (en) 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
WO2006014325A2 (en) * 2004-07-02 2006-02-09 Exelixis, Inc. C-met modulators and method of use
MX2007000631A (es) 2004-07-16 2007-03-30 Sunesis Pharmaceuticals Inc Tienopirimidinas utiles como inhibidores de aurora cinasa.
CA2573538C (en) * 2004-07-30 2014-11-25 Methylgene Inc. Inhibitors of vegf receptor and hgf receptor signaling
US7647492B2 (en) 2004-09-15 2010-01-12 Check Point Software Technologies Inc. Architecture for routing and IPSec integration
EP1844062A2 (en) 2005-01-21 2007-10-17 Methylgene, Inc. Inhibitors of dna methyltransferase
AU2006229343A1 (en) 2005-03-28 2006-10-05 Kirin Pharma Kabushiki Kaisha Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-Met autophosphorylation inhibiting potency
JO2787B1 (en) * 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
TW200740820A (en) 2005-07-05 2007-11-01 Takeda Pharmaceuticals Co Fused heterocyclic derivatives and use thereof
DE102005037499A1 (de) 2005-08-09 2007-02-15 Merck Patent Gmbh Pyrazolderivate
BRPI0620040A2 (pt) 2005-12-19 2011-10-25 Methylgene Inc inibidores de histona desacetilase para realçar a atividade de agentes antifúngicos
AR059246A1 (es) 2006-01-30 2008-03-19 Array Biopharma Inc Compuestos heterobiciclicos de tiofeno y metodos de uso
WO2007107005A1 (en) * 2006-03-22 2007-09-27 Methylgene, Inc. Inhibitors of protein tyrosine kinase activity

Also Published As

Publication number Publication date
BRPI0610322B1 (pt) 2020-12-01
MX2007014616A (es) 2009-08-12
CN101796055B (zh) 2013-09-04
ES2623221T3 (es) 2017-07-10
KR101378716B1 (ko) 2014-04-10
IL187484A0 (en) 2011-08-01
EP1957498A4 (en) 2010-10-27
CA2611370A1 (en) 2006-11-20
US8329726B2 (en) 2012-12-11
EP1957498B1 (en) 2017-02-15
US20120083482A1 (en) 2012-04-05
BRPI0610322A2 (pt) 2010-06-15
CA2611370C (en) 2014-11-25
CN101796055A (zh) 2010-08-04
JP5148499B2 (ja) 2013-02-20
AU2006343808B2 (en) 2012-03-29
WO2008041053A2 (en) 2008-04-10
IL187484A (en) 2014-04-30
AU2006343808A1 (en) 2008-04-10
US8093264B2 (en) 2012-01-10
EP1957498A2 (en) 2008-08-20
WO2008041053A3 (en) 2009-12-23
JP2009504804A (ja) 2009-02-05
NZ564283A (en) 2011-07-29
US20070004675A1 (en) 2007-01-04
KR20080059112A (ko) 2008-06-26

Similar Documents

Publication Publication Date Title
MX2007014616A (es) Inhibidores de señalizacion del receptor del factor a de crecimiento endotelial vascular y del receptor del factor de crecimiento de hepatocitos.
BRPI0513982A (pt) inibidores de sinalização de receptor de vegf e receptor de hgf
TN2009000255A1 (en) Quinazolines for pdk1 inhibition
BR112013011441A2 (pt) composto, composição farmacêutica, e, uso de um composto
CL2008003798A1 (es) Compuestos derivados de heterobiciclos aromaticos sustituidos, inhibidores de pi3 quinasa; composicion farmaceutica; utiles en el tratamiento de cancer, melanomas, glioblastomas, entre otras enfermedades.
BRPI0710521A2 (pt) quinazolinas para inibição de pdk1
ECSP088804A (es) Antagonistas de los piridil amida de los canales de calcio de tipo t
BR112012007747A2 (pt) Compostos heterocíclicos úteis como inibidores de pdk1, sua composição farmacêutica e seus usos
EA200702339A1 (ru) Замещенные амидные производные в качестве ингибиторов протеинкиназы
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
BRPI0615097A2 (pt) agentes para previnir e tratar distúrbios que envolvem modulação dos receptores de ryr
ECSP10010035A (es) Amidas heterocíclicas y sus métodos de uso
EA200900798A1 (ru) Производные индол-4-илпиримидинил-2-иламина и их применение в качестве ингибиторов циклинзависимой киназы
BRPI0819218A2 (pt) Métodos, estojos e composições para administração de compostos farmacêuticos
CL2008003339A1 (es) Compuestos derivados de pirimidin-2(1h)-ona, inhibidores de la 11b-hidroxiesteroide deshidrogenasa 1; composicion farmaceutica, util para el tratamiento de enfermedades tales como obesidad, hipertension e hiperlipidemia.
BR112013004368A2 (pt) compostos tendo a fórmula geral (i) e composição farmacêutica
DOP2012000006A (es) Agonista de gpr119
CL2007003758A1 (es) Compuestos derivados de aminopirimidina, inhibidores de plk1; composicion farmaceutica, util para el tratamiento de cancer.
WO2007054831A3 (en) Inhibitors of vegf receptor and hgf receptor signaling
CL2008000021A1 (es) Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer.
DOP2007000053A (es) Compuestos de tetrahidropiridotienopirimidina y métodos para su empleo
SV2010003650A (es) INHIBIDORES HETEROCICLICOS DE ESTEAROIL-CoA-DESATURASA
UY31322A1 (es) Amidas heterocíclicas y sus métodos de uso-975

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: APRESENTE O DEPOSITANTE COPIA DA FOLHA DE ROSTO DA PUBLICACAO INTERNACIONAL DO PEDIDO, CONFORME O DISPOSTO NO ITEM 9.3 DO AN NO 128/1997.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 01/12/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/05/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF